

Drugs for Non-small Cell Lung Cancer-Global Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/D318A4B5F8BMEN.html>

Date: May 2018

Pages: 148

Price: US\$ 2,480.00 (Single User License)

ID: D318A4B5F8BMEN

Abstracts

Report Summary

Drugs for Non-small Cell Lung Cancer-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Drugs for Non-small Cell Lung Cancer industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Drugs for Non-small Cell Lung Cancer 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Drugs for Non-small Cell Lung Cancer worldwide, with company and product introduction, position in the Drugs for Non-small Cell Lung Cancer market

Market status and development trend of Drugs for Non-small Cell Lung Cancer by types and applications

Cost and profit status of Drugs for Non-small Cell Lung Cancer, and marketing status

Market growth drivers and challenges

The report segments the global Drugs for Non-small Cell Lung Cancer market as:

Global Drugs for Non-small Cell Lung Cancer Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC

Latin America

Global Drugs for Non-small Cell Lung Cancer Market: Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Radiofrequency Ablation (RFA)

Radiation Therapy

Chemotherapy

Targeted Therapies

Immunotherapy

Global Drugs for Non-small Cell Lung Cancer Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Hospital

Clinic

Other

Global Drugs for Non-small Cell Lung Cancer Market: Manufacturers Segment Analysis
(Company and Product introduction, Drugs for Non-small Cell Lung Cancer Sales
Volume, Revenue, Price and Gross Margin):

Bristol-Myers Squibb

GlaxoSmithKline

Menarini

Sanofi

Ziopharm Oncology

Alchemia

Amgen

Apotex

BioMarin Pharmaceutical

CellAct Pharma

Cerulean Pharma

Cipla

Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF DRUGS FOR NON-SMALL CELL LUNG CANCER

- 1.1 Definition of Drugs for Non-small Cell Lung Cancer in This Report
- 1.2 Commercial Types of Drugs for Non-small Cell Lung Cancer
 - 1.2.1 Radiofrequency Ablation (RFA)
 - 1.2.2 Radiation Therapy
 - 1.2.3 Chemotherapy
 - 1.2.4 Targeted Therapies
 - 1.2.5 Immunotherapy
- 1.3 Downstream Application of Drugs for Non-small Cell Lung Cancer
 - 1.3.1 Hospital
 - 1.3.2 Clinic
 - 1.3.3 Other
- 1.4 Development History of Drugs for Non-small Cell Lung Cancer
- 1.5 Market Status and Trend of Drugs for Non-small Cell Lung Cancer 2013-2023
 - 1.5.1 Global Drugs for Non-small Cell Lung Cancer Market Status and Trend 2013-2023
 - 1.5.2 Regional Drugs for Non-small Cell Lung Cancer Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Drugs for Non-small Cell Lung Cancer 2013-2017
- 2.2 Sales Market of Drugs for Non-small Cell Lung Cancer by Regions
 - 2.2.1 Sales Volume of Drugs for Non-small Cell Lung Cancer by Regions
 - 2.2.2 Sales Value of Drugs for Non-small Cell Lung Cancer by Regions
- 2.3 Production Market of Drugs for Non-small Cell Lung Cancer by Regions
- 2.4 Global Market Forecast of Drugs for Non-small Cell Lung Cancer 2018-2023
 - 2.4.1 Global Market Forecast of Drugs for Non-small Cell Lung Cancer 2018-2023
 - 2.4.2 Market Forecast of Drugs for Non-small Cell Lung Cancer by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Drugs for Non-small Cell Lung Cancer by Types
- 3.2 Sales Value of Drugs for Non-small Cell Lung Cancer by Types
- 3.3 Market Forecast of Drugs for Non-small Cell Lung Cancer by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Global Sales Volume of Drugs for Non-small Cell Lung Cancer by Downstream Industry

4.2 Global Market Forecast of Drugs for Non-small Cell Lung Cancer by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

5.1 North America Drugs for Non-small Cell Lung Cancer Market Status by Countries

5.1.1 North America Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)

5.1.2 North America Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)

5.1.3 United States Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

5.1.4 Canada Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

5.1.5 Mexico Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

5.2 North America Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers

5.3 North America Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)

5.3.1 North America Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)

5.3.2 North America Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)

5.4 North America Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

6.1 Europe Drugs for Non-small Cell Lung Cancer Market Status by Countries

6.1.1 Europe Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)

6.1.2 Europe Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)

6.1.3 Germany Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

6.1.4 UK Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

6.1.5 France Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

- 6.1.6 Italy Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
- 6.1.7 Russia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
- 6.1.8 Spain Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
- 6.1.9 Benelux Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
- 6.2 Europe Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
- 6.3 Europe Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
 - 6.3.1 Europe Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
 - 6.3.2 Europe Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
- 6.4 Europe Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Countries
 - 7.1.1 Asia Pacific Drugs for Non-small Cell Lung Cancer Sales by Countries (2013-2017)
 - 7.1.2 Asia Pacific Drugs for Non-small Cell Lung Cancer Revenue by Countries (2013-2017)
 - 7.1.3 China Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
 - 7.1.4 Japan Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
 - 7.1.5 India Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
 - 7.1.6 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
 - 7.1.7 Australia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)
- 7.2 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Manufacturers
- 7.3 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Type (2013-2017)
 - 7.3.1 Asia Pacific Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)
 - 7.3.2 Asia Pacific Drugs for Non-small Cell Lung Cancer Revenue by Type (2013-2017)
- 7.4 Asia Pacific Drugs for Non-small Cell Lung Cancer Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Countries
 - 8.1.1 Latin America Drugs for Non-small Cell Lung Cancer Sales by Countries

(2013-2017)

8.1.2 Latin America Drugs for Non-small Cell Lung Cancer Revenue by Countries

(2013-2017)

8.1.3 Brazil Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

8.1.4 Argentina Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

8.1.5 Colombia Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

8.2 Latin America Drugs for Non-small Cell Lung Cancer Market Status by
Manufacturers

8.3 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Type
(2013-2017)

8.3.1 Latin America Drugs for Non-small Cell Lung Cancer Sales by Type (2013-2017)

8.3.2 Latin America Drugs for Non-small Cell Lung Cancer Revenue by Type
(2013-2017)

8.4 Latin America Drugs for Non-small Cell Lung Cancer Market Status by Downstream
Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

9.1 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by
Countries

9.1.1 Middle East and Africa Drugs for Non-small Cell Lung Cancer Sales by Countries
(2013-2017)

9.1.2 Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue by
Countries (2013-2017)

9.1.3 Middle East Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

9.1.4 Africa Drugs for Non-small Cell Lung Cancer Market Status (2013-2017)

9.2 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by
Manufacturers

9.3 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by
Type (2013-2017)

9.3.1 Middle East and Africa Drugs for Non-small Cell Lung Cancer Sales by Type
(2013-2017)

9.3.2 Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue by Type
(2013-2017)

9.4 Middle East and Africa Drugs for Non-small Cell Lung Cancer Market Status by
Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF DRUGS FOR NON-

SMALL CELL LUNG CANCER

10.1 Global Economy Situation and Trend Overview

10.2 Drugs for Non-small Cell Lung Cancer Downstream Industry Situation and Trend Overview

CHAPTER 11 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

11.1 Production Volume of Drugs for Non-small Cell Lung Cancer by Major Manufacturers

11.2 Production Value of Drugs for Non-small Cell Lung Cancer by Major Manufacturers

11.3 Basic Information of Drugs for Non-small Cell Lung Cancer by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Drugs for Non-small Cell Lung Cancer Major Manufacturer

11.3.2 Employees and Revenue Level of Drugs for Non-small Cell Lung Cancer Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

CHAPTER 12 DRUGS FOR NON-SMALL CELL LUNG CANCER MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

12.1 Bristol-Myers Squibb

12.1.1 Company profile

12.1.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.1.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb

12.2 GlaxoSmithKline

12.2.1 Company profile

12.2.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.2.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

12.3 Menarini

12.3.1 Company profile

12.3.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.3.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Menarini

12.4 Sanofi

12.4.1 Company profile

12.4.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.4.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Sanofi

12.5 Ziopharm Oncology

12.5.1 Company profile

12.5.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.5.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Ziopharm Oncology

12.6 Alchemia

12.6.1 Company profile

12.6.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.6.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Alchemia

12.7 Amgen

12.7.1 Company profile

12.7.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.7.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Amgen

12.8 Apotex

12.8.1 Company profile

12.8.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.8.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Apotex

12.9 BioMarin Pharmaceutical

12.9.1 Company profile

12.9.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.9.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of BioMarin Pharmaceutical

12.10 CellAct Pharma

12.10.1 Company profile

12.10.2 Representative Drugs for Non-small Cell Lung Cancer Product

12.10.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of CellAct Pharma

12.11 Cerulean Pharma

12.11.1 Company profile

- 12.11.2 Representative Drugs for Non-small Cell Lung Cancer Product
- 12.11.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cerulean Pharma
- 12.12 Cipla
 - 12.12.1 Company profile
 - 12.12.2 Representative Drugs for Non-small Cell Lung Cancer Product
 - 12.12.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cipla
- 12.13 Cornerstone Pharmaceuticals
 - 12.13.1 Company profile
 - 12.13.2 Representative Drugs for Non-small Cell Lung Cancer Product
 - 12.13.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Cornerstone Pharmaceuticals
- 12.14 Curis
 - 12.14.1 Company profile
 - 12.14.2 Representative Drugs for Non-small Cell Lung Cancer Product
 - 12.14.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of Curis
- 12.15 CytRx
 - 12.15.1 Company profile
 - 12.15.2 Representative Drugs for Non-small Cell Lung Cancer Product
 - 12.15.3 Drugs for Non-small Cell Lung Cancer Sales, Revenue, Price and Gross Margin of CytRx
- 12.16 Eli Lilly
- 12.17 Exelixis
- 12.18 Fresenius Kabi
- 12.19 Genentech
- 12.20 Hikma Pharmaceuticals
- 12.21 Hospira
- 12.22 Intas Pharmaceuticals
- 12.23 Karyopharm Therapeutics
- 12.24 Kyowa Hakko Kirin
- 12.25 Ligand Pharmaceuticals

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER

- 13.1 Industry Chain of Drugs for Non-small Cell Lung Cancer
- 13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF DRUGS FOR NON-SMALL CELL LUNG CANCER

14.1 Cost Structure Analysis of Drugs for Non-small Cell Lung Cancer

14.2 Raw Materials Cost Analysis of Drugs for Non-small Cell Lung Cancer

14.3 Labor Cost Analysis of Drugs for Non-small Cell Lung Cancer

14.4 Manufacturing Expenses Analysis of Drugs for Non-small Cell Lung Cancer

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

16.1 Methodology/Research Approach

16.1.1 Research Programs/Design

16.1.2 Market Size Estimation

16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

16.2.1 Secondary Sources

16.2.2 Primary Sources

16.3 Reference

I would like to order

Product name: Drugs for Non-small Cell Lung Cancer-Global Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/D318A4B5F8BMEN.html>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D318A4B5F8BMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970